ZA200900553B - Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions - Google Patents

Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions

Info

Publication number
ZA200900553B
ZA200900553B ZA200900553A ZA200900553A ZA200900553B ZA 200900553 B ZA200900553 B ZA 200900553B ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 B ZA200900553 B ZA 200900553B
Authority
ZA
South Africa
Prior art keywords
gremlin
iop
rnai
treatment
related conditions
Prior art date
Application number
ZA200900553A
Other languages
English (en)
Inventor
Jon E Chatterton
Abbot F Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200900553B publication Critical patent/ZA200900553B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200900553A 2006-08-24 2007-08-24 Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions ZA200900553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24

Publications (1)

Publication Number Publication Date
ZA200900553B true ZA200900553B (en) 2010-04-28

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900553A ZA200900553B (en) 2006-08-24 2007-08-24 Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions

Country Status (11)

Country Link
US (3) US20080051361A1 (enExample)
EP (1) EP2059597A2 (enExample)
JP (1) JP2010501188A (enExample)
KR (1) KR20090042297A (enExample)
CN (2) CN102743767A (enExample)
AU (1) AU2007286545A1 (enExample)
BR (1) BRPI0715821A2 (enExample)
CA (1) CA2659464A1 (enExample)
MX (1) MX2009001896A (enExample)
WO (1) WO2008024983A2 (enExample)
ZA (1) ZA200900553B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
WO2009046059A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8778904B2 (en) * 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
RU2599449C1 (ru) 2011-12-15 2016-10-10 Байонир Корпорейшн Новые конъюгаты олигонуклеотидов и их применение
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
JP6060178B2 (ja) 2012-01-05 2017-01-18 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法
JP5906327B2 (ja) 2012-01-18 2016-04-20 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法
TR201905395T4 (tr) * 2012-03-15 2019-05-21 Hyun Kee Kim Anti-gremlin-1 antikoru.
IN2015DN02699A (enExample) * 2012-09-05 2015-09-04 Sylentis Sau
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US10030243B2 (en) 2013-07-05 2018-07-24 Bioneer Corporation Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685055A (zh) * 2001-10-31 2005-10-19 爱尔康公司 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets

Also Published As

Publication number Publication date
CA2659464A1 (en) 2008-02-28
WO2008024983A3 (en) 2008-10-09
BRPI0715821A2 (pt) 2013-07-23
MX2009001896A (es) 2009-04-17
AU2007286545A1 (en) 2008-02-28
CN101517081A (zh) 2009-08-26
US20120077864A1 (en) 2012-03-29
EP2059597A2 (en) 2009-05-20
JP2010501188A (ja) 2010-01-21
US20080051361A1 (en) 2008-02-28
WO2008024983A2 (en) 2008-02-28
US20100305193A1 (en) 2010-12-02
KR20090042297A (ko) 2009-04-29
CN102743767A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
ZA200900553B (en) Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions
IL194114A0 (en) Treatment of cns conditions
GB2454797B (en) Treatment of wastewater
ZA200900884B (en) Method of scale inhibition
EP2032131A4 (en) Methods of Treatment
SG10201601846VA (en) Rnai inhibition of alpha-enac expression
PL2029155T3 (pl) Ulepszony sposób leczenia szpiczaka mnogiego
IL195803A0 (en) Compositions and methods for sirna inhibition of angiogenesis
ZA200809203B (en) Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
ZA200901364B (en) Method of treatment of photodermatoses
EP2215035A4 (en) BISULFIT TREATMENT OF RNA
ZA201008192B (en) A phytosystem for treatment of sewage
EP2013404A4 (en) OPERATING PROCESS FOR DRYERS
EP2072470A4 (en) PROCESS FOR RECYCLING WASTEWATER
GB0610746D0 (en) Method of treatment
GB0608190D0 (en) Method of purification
GB0701722D0 (en) Inhibition of gene expression
EP2164494A4 (en) Methods of Treatment
GB0605685D0 (en) Inhibition of tumour growth
EP2188219A4 (en) METHOD FOR WATER TREATMENT COMPRISING NON-POLAR COMPOUNDS
GB0723100D0 (en) Treatment of HFnEF
ZA200805601B (en) RNAI-mediated inhibition of IGF1R for treatment of ocular angiogenesis
EP2344424A4 (en) ELIMINATION OF ARSENIC FROM WATER
EP2094385A4 (en) METHOD OF WASTE WATER TREATMENT
ZA200903242B (en) Treatment for multiple myeloma